throbber
CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`
`020592Orig1s040s041
`
`
`OTHER REVIEW(S)
`
`

`

`Department of Health and Human Services
`Public Health Service
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Surveillance and Epidemiology
`
`
`
`October 1, 2009
`Thomas Laughren, MD, Director
`Division of Psychiatry Products (DPP)
`Claudia Karwoski, PharmD, Director
`Division of Risk Management (DRISK)
`
`LaShawn Griffiths, MSHS-PH, BSN, RN
`Patient Product Information Reviewer, Acting Team Leader
`Division of Risk Management
`Sharon R. Mills, BSN,RN, CCRP
`Senior Patient Product Information Reviewer, Acting Team
`Leader
`Division of Risk Management
`DRISK Review of Patient Labeling (Medication Guide),
`Zyprexa (olanzapine) Tablet and Zyprexa Zydis (olanzapine)
`Tablet, Orally Disintegrating
`NDA 20-592
`
`S-040 and S-041
`Eli Lilly and Company
`2009-1412
`
`Date:
`To:
`
`Through:
`
`From:
`
`Subject:
`Drug Name(s):
`
`Application
`Type/Number:
`Submission Number:
`Applicant/sponsor:
`OSE RCM #:
`
`
`

`

`1
`
`INTRODUCTION
`This review is written in response to a request by the Division of Psychiatry
`Products (DPP) for the Division of Risk Management (DRISK) to review the
`Applicant’s proposed Medication Guide (MG) for Zyprexa (olanzapine) Tablet and
`Zyprexa Zydis (olanzapine) Tablet, Orally Disintegrating. Please let us know if DPP
`would like a meeting to discuss this review or any of our changes prior to sending to
`the Applicant. The proposed REMS revision is being reviewed by DRISK and will be
`provided to DPP under separate cover.
`
` 2
`
` MATERIAL REVIEWED
`(cid:131) Draft Zyprexa (olanzapine) Tablet and Zyprexa Zydis (olanzapine) Tablet, Orally
`Disintegrating Prescribing Information (PI) submitted May 5, 2009 and revised by
`the Review Division throughout the current review cycle, most recent revision
`dated September 9, 2009.
`(cid:131) Draft Zyprexa (olanzapine) Tablet and Zyprexa Zydis (olanzapine) Tablet, Orally
`Disintegrating Medication Guide (MG) submitted on May 5, 2009 and revised by
`the review division throughout the review cycle, most recent version dated
`September 9, 2009.
`3 RESULTS OF REVIEW
`Since DRISK previously reviewed the Zyprexa MG in February 2009 and March
`2009, we have limited this review to the identified PI revisions, in particular relating
`to the addition of information about adolescents, and changes to the Indications for
`Use. In our review of the MG we have:
`simplified wording and clarified concepts where possible
`•
`• made minimal reformatting changes to enhance readability
`ensured that the MG is consistent with the PI
`•
`•
`ensured that the MG meets the Regulations as specified in 21 CFR 208.20
`•
`ensured that the MG meets the criteria as specified in FDA’s Guidance for
`Useful Written Consumer Medication Information (published July 2006)
`
`
`Our annotated MG is appended to this memo. Any additional revisions to the PI
`should be reflected in the MG.
`
`
`Please let us know if you have any questions.
`
`
`
`
`
`
`1
`
`9 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following
`this page
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`SHARON R MILLS
`10/01/2009
`
`CLAUDIA B KARWOSKI
`10/01/2009
`concur
`
`

`

`Department of Health and Human Services
`Public Health Service
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Surveillance and Epidemiology
`
`
`
`Date:
`To:
`
`Thru:
`
`From:
`
`September 3, 2009
`M. Dianne Murphy, MD
`Director, Office of Pediatric Therapeutics (OPT), OIASI
`Office of the Commissioner
`
`CDR Lisa L. Mathis, USPHS, MD
`Associate Director, Pediatric and Maternal Health Team (PMHS)
`Office of New Drugs
`Laura Governale, Pharm.D., MBA
`Drug Use Data Analyst Team Leader
`Division of Epidemiology
`Office of Surveillance and Epidemiology
`Hina Mehta, Pharm.D.
`Drug Use Data Analyst
`Division of Epidemiology
`Office of Surveillance and Epidemiology
`Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel®
`(quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone),
`Invega® (paliperidone) Drug Use Review
`Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel®
`(quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone),
`Invega® (paliperidone)
`Application Type/Number: Various
`Applicant/sponsor:
`Various
`OSE RCM #:
`2009-1004
`**This document contains proprietary drug use data obtained by FDA under contract. The drug use
`data/information cannot be released to the public/non-FDA personnel without contractor approval obtained
`through the FDA/CDER Office of Surveillance and Epidemiology.**
`
`
`Subject:
`
`Drug Name(s):
`
`

`

`EXECUTIVE SUMMARY
`This review examines drug utilization patterns for six atypical antipsychotics, Abilify® (aripiprazole),
`Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega®
`(paliperidone), in the pediatric population (age 0-2 years, 3-6 years, 7-12 years, 13-17 years, and 18+ years)
`from year 2004 through June 2009. Since approximately
` of the atypical antipsychotics were sold
`to U.S. outpatient retail settings during year 2008, this review focuses on the outpatient setting.
`• All of the antipsychotic agents studied except for
` had an increase in the number of
`dispensed prescriptions over the past 5 years.
`• Dispensed prescriptions for
` increased the most by approximately % from year 2004
`to year 2008.
`• Antipsychotic use among pediatric patients has increased by % over the 5 years. The greatest
`increase was seen for
` during this time period.
` had the most prescriptions dispensed %) to pediatric patients (0-17 years) and had a
`greater amount of use in younger children compared to the other antipsychotics.
` had
`the second highest number of dispensed prescriptions %) in the pediatric population.
`In year 2008,
` unique patients received a prescription for
` followed by
` with
` and
` with
`.
`• For all of the agents studied, the majority of prescriptions dispensed to patients over the entire study
`period were prescribed by Psychiatrists.
`In children aged 7-12 years old, concomitant use with stimulant medications were most common for
`those already on
` Mood stabilizing agents, other
`antipsychotics and antidepressants were the most common concomitant products for
` in this age group as well as for older age groups.
`
`
`
` 1
`
`
`INTRODUCTION
`Using the currently available proprietary drug use databases licensed by the Agency, this review describes
`outpatient drug use patterns for Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine),
`Zyprexa® (olanzapine), Risperdal® (risperidone), Invega® (paliperidone) in the pediatric population as well as
`in the adult population for years 2004 through 2008 and year-to-date June 2009.
`
`2 METHODS AND MATERIALS
`
`2.1 DETERMINING SETTINGS OF CARE
`IMS Health, IMS National Sales Perspectives™ data (see Appendix 2) were used to determine the setting
`in which these six atypical antipsychotic products were sold. Sales of these products by number of bottles,
`packets of pills (eaches) sold from the manufacturer into the various retail and non-retail channels of
`distribution were analyzed for year 2008 (data not provided).1 During the review period, retail settings (chain
`stores, independent pharmacies, and food stores) accounted for the majority of atypical antipsychotic product
`sales % or greater). Distribution towards non-retail pharmacy settings ranged from
`% during
`year 2008. The long term care setting within the non-retail channels received the majority of atypical
`antipsychotic sales. Mail order distribution ranged from
`% for the six agents analyzed. Thus, we
`examined outpatient utilization patterns. Mail order and long term care data are not included in this analysis.
`
`1 IMS Health, IMS Nationals Sales PerspectivesTM, Years 2004-2008, Data extracted Aug 2009, Source file: 0908apsy.DVR
`
`•
`
`•
`
`•
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`2.2 DATA SOURCES USED
`
`Outpatient use and patient demographics (stratified by ages 0-2 years, 3-6 years, 7-12 years, 13-17 years, and
`18+ years) were measured from SDI Vector One®: National (VONA) and Total Patient Tracker (TPT)
`(Appendix 2). Indications for use were obtained from the SDI’s Physician’s Drug and Diagnosis Audit
`(PDDA) (Appendix 2). From these data sources, estimates of the number of prescriptions dispensed, the
`number of patients who received a prescription for Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel®
`(quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega® (paliperidone), and the number of
`drug mentions by office-based physicians, were obtained for years 2004-2008 and year-to-date June 2009.
`
`3 RESULTS
`
`3.1 DISPENSED PRESCRIPTIONS
`Figure 1 in Appendix 1 shows the total number of prescriptions dispensed in the outpatient retail setting
`(mail order excluded) for Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa®
`(olanzapine), Risperdal® (risperidone), Invega® (paliperidone). During year 2008, nearly
`
`prescriptions were dispensed for these products, an increase of % from approximately
`dispensed prescriptions in year 2004. Approximately
` prescriptions were dispensed for
`% of market) followed by
`% of market) and
`% of market) with
` prescriptions, respectively. All of the agents had an increase in the number of
`prescriptions dispensed in the past 5 years except for
`which decreased by abou
` during the
`same time period. Dispensed prescriptions for
`increased by % from year 2004
`
`prescriptions) to year 2008 (
` prescriptions) followed by
` with % increase and
` with % increase.
`
`
`
`3.2 DISPENSED PRESCRIPTION BY PEDIATRIC AGE GROUPS
`Antipsychotic use in the pediatric population (0-17 years) has increased % in the past 5 years (Figure 2:
`Appendix 1). The greatest increase was seen for
`%. In year 2008, of the six agents
`analyzed,
` had the most prescriptions dispensed to pediatric patients aged 0-17 years % of all
` dispensed to pediatric patients versus adults
` risperidone prescriptions), followed by
`%;
` prescriptions),
` prescriptions),
`
`
` prescriptions), and
` prescriptions),
`prescriptions). Analysis of pediatric sub-age groups revealed that the majority of antipsychotic use during
`year 2008 was among those aged
`years;
`
`.
`, on the other hand, was most commonly dispensed to
`pediatric patients aged 7-12 years, accounting for % of dispensed prescriptions. Prescriptions dispensed to
`pediatric patients aged 0-2 years and 3-6 years accounted for less than
` of the combined total dispensed
`prescriptions for all six agents with the exception of
` in which
` of prescriptions are dispensed
`to pediatrics aged 3-6 years (Table 1: Appendix 1).
`
`3.3 PATIENT-LEVEL DATA
`Trends for patient data were similar to that of prescription data. In year 2008, approximately
`patients received a prescription for these selected antipsychotic agents in the outpatient retail pharmacy
`setting, an increase of % from
` patients in year 2004. Approximately,
` unique
`
`patients received a prescription for
` respectively. As with dispensed prescription data, analysis of pediatric sub-age groups revealed
`similar trends in use with patient-level data (Table 2: Appendix 1).
`
`
`
`3.4 DIAGNOSES ASSOCIATED WITH USE
`
`
`
`2
`
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`We also examined the most common diagnosis associated with the use of Abilify® (aripiprazole), Geodon®
`(ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega®
`(paliperidone) as reported by office-based physician practices in the U.S. (Appendix 1: Tables 3a-3e).
`Diagnoses among the pediatric age groups 0-2 years and 3-6 years were below the acceptable count
`
`allowable to provide a reliable estimate. Among the pediatrics aged 7-12 years “
` was the most common diagnosis associated with a mention of aripiprazole with approximately
`% of all mentions for that age group from year 2004 through year to date June 2009 followed by
` with %. For risperidone, the most common diagnosis among
` with % followed by “
`
`pediatrics aged 7-12 years was “
` with
`%, respectively. For
` and
`adolescents aged 13-17 years the most common diagnosis associated with a mention for aripiprazole,
`quetiapine, olanzapine, and ziprasidone was “
`
`
`
`paliperidone, respectively, for this age group.
`
` were the most common diagnosis for risperidone and
`
`3.5 PEDIATRIC DISPENSED PRESCRIPTION BY PRESCRIBING SPECIALTY
`Table 4a-4f in Appendix 1 shows the total number of prescriptions dispensed for Abilify® (aripiprazole),
`Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa® (olanzapine), Risperdal® (risperidone), Invega®
`(paliperidone) by patient age and physician specialty. The majority of prescriptions dispensed to patients
`were prescribed by Psychiatrists over the entire study period for the pediatric as well as adult age groups for
`all of the agents studied. During year 2008, Nurse Practitioners were the second most common prescriber for
`aripiprazole, ziprasidone and paliperidone for both adult and pediatric age groups. For risperidone,
`quetiapine, and olanzapine, GP/FM/DO2 were the second most common prescribers of these medications to
`both adult and pediatric age groups.
`
`3.6 CONCOMITANT USE
`Tables 5a-5e in Appendix 1 shows the total number of health care physician mentions where one of the select
`antipsychotics were used concomitantly with another class of products to treat the same diagnosis.
`Concomitancy for all of the agents among the pediatric age groups 0-2 years and 3-6 years were below the
`acceptable count allowable to provide a reliable estimate of use. In those aged 7-12 years old, concomitant
`use with stimulant medications were most common for
`. For
` mood stabilizing agents such as anticonvulsants, other antipsychotics, and
`antidepressants were commonly used together to treat the same diagnosis. In those aged 13-17 years,
`concomitant use with mood stabilizing agents, other antipsychotics and antidepressants were the most
`common concomitant class of products for all antipsychotic agents studied.
`
`4 LIMITATIONS
`Findings from this consult should be interpreted in the context of the known limitations of the databases
`used. We estimated Abilify® (aripiprazole), Geodon® (ziprasidone), Seroquel® (quetiapine), Zyprexa®
`(olanzapine), Risperdal® (risperidone), Invega® (paliperidone) are distributed primarily in outpatient settings
`based on the IMS Health, IMS National Sales Perspectives™. These data do not provide a direct estimate of
`use but do provide a national estimate of units sold from the manufacturer into the various channels of
`distribution. The amount of product purchased by these retail and non-retail channels of distribution may be a
`possible surrogate for use, if we assume the facilities purchase drugs in quantities reflective of actual patient
`use.
`SDI’s Physician Drug & Diagnosis Audit (PDDA) data provide estimates of patient demographics and
`indications for use of medicinal products in the U.S. Due to the sampling and data collection methodologies,
`
`
`2 GP/FM/DO – General Practice, Family Medicine, Doctor of Osteopathy
`
`
`
`3
`
`
`(b)
`(4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`the small sample size can make these data unstable, particularly if use is not common in the pediatric
`population. SDI recommends caution interpreting projected annual uses or mentions below 100,000 as the
`sample size is very small with correspondingly large confidence intervals.
`
`5 CONCLUSIONS
` had an increase in the number of dispensed
`All of the antipsychotic agents studied except for
`prescriptions over the past 5 years. Dispensed prescription for
`) increased the greatest
`amount
`%). Antipsychotic use among pediatric patients aged 0-17 years have increased % over the
`past 5 years. Use among pediatrics aged 0-2 years and 3-6 years accounted for less than
` of the total for
`each of the antipsychotic agents studied.
` was the most commonly dispensed atypical
`antipsychotic agent among pediatrics, especially those aged 7-12 years.
` pediatric prescriptions
`are most commonly dispensed to adolescents aged 13-17 years. Trends for patient data were similar to that
`of prescription data. Psychiatrists prescribe the majority of antipsychotic prescriptions dispensed. In
`younger children (7-12 years old), concomitant use with stimulant medications were most common for
`. Mood stabilizing agents, other antipsychotics and antidepressants
`were the most common concomitant class of products used with
` in this age group
`as well as for older age groups.
`
`
`
`4
`
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b
`)
`(4
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`APPENDICES
`APPENDIX 1: Figures and Tables
`
`
`Figure 1: Total Number of Dispensed Prescriptions for 6 Atypical Antipsychotic Agents
`Through U.S. Outpatient Retail Pharmacies, Years 2004-2008 and YTD Jun 2009
`
` quetiapine fumarate
` risperidone
` aripiprazole
` olanzapine
` ziprasidone hcl
` paliperidone
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`YTD/JUN/2009
`
`Year
`Source: SDI: Vector One®: National. Data Extracted 8-4-09. File: VONA 2009-1004 TRx 8-4-09.qry
`
`
`
`14,000,000
`
`12,000,000
`
`10,000,000
`
`8,000,000
`
`6,000,000
`
`TRx
`
`4,000,000
`
`2,000,000
`
`0
`
`
`
`5
`
`
`(b) (4)
`
`

`

`Figure 2: Total Number of Prescriptions Dispensed for 6 Atypical Antipsychotics Among
`Pediatrics 0-17 Years Through U.S. Outpatient Retail Pharmacies, 2004-2008 and YTD Jun
`2009
`
`TOTAL MARKET
` risperidone
` aripiprazole
` quetiapine fumarate
` ziprasidone hcl
` olanzapine
` paliperidone
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`YTD/JUN/2009
`
`Year
`Source: SDI: Vector One: National. Data Extracted 9-1-09. File: VONA 2009-1004 TRx by Ages 0-17 only 9-1-
`09.qry
`
`
`
`6,000,000
`
`5,000,000
`
`4,000,000
`
`3,000,000
`
`TRx
`
`2,000,000
`
`1,000,000
`
`0
`
`
`
`6
`
`
`(b) (4)
`
`

`

`Table 1: Total Number of Prescriptions Dispensed for Atypical Antipsychotics Through U.S. Outpatient Retail Pharmacies, Years 2004-2008 and YTD 2009
`2004
`2005
`2006
`2007
`2008
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TOTAL MARKET
`
`YTD/JUN/2009
`Share
`TRxs
`%
`N
`
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` Age UNSPEC.
`
`Source: SDI: Vector One®: National. Data Extracted 8-4-09. File: VONA 2009-1004 TRx by Age 8-4-09.qry
`
`
`
`
`
`
`
`
`
`
`7
`
`
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 2. Total Number of Unique Patients Receiving a Prescription for Atypical Antipsychotics Through U.S. Outpatient Retail Pharmacies, 2004-2008 and YTD 2009
`2004
`2005
`2006
`2007
`2008
`YTD/Jun/2009
`%
`N
`
`
`Total Market
`
`N
`
`%
`
`N
`
`%
`
`N
`
`%
`
`N
`
`%
`
`N
`
`%
`
`Age 0 - 2
`Age 3 - 6
`Age 7 - 12
`Age 13 - 17
`Age 18+
`Age Unknown
`
`Source: SDI: Total Patient Tracker. Data Extracted 8-5-09 and 8-6-09. Files: TPT 2009-1004 Abilify Patient Count by Age 8-5-09.xls, TPT 2009-1004 Abilify Patient Count by Age YTD 2009
`8-5-09.xls, TPT 2009-1004 Geodon Patient Count by Age 8-5-09.xls, TPT 2009-1004 Geodon Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Invega Patient Count by Age 8-5-09.xls,
`TPT 2009-1004 Invega Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Risperdal Patient Count by Age 8-5-09.xls, TPT 2009-1004 Risperdal Patient Count by Age YTD 2009
`8-5-09.xls, TPT 2009-1004 Seroquel Patient Count by Age 8--5-09.xls, TPT 2009-1004 Seroquel Patient Count by Age YTD 2009 8-5-09.xls, TPT 2009-1004 Total Patient Count 8-6-09.xls,
`TPT 2009-1004 Total Patient Count YTD 2009 8-6-09.xls, TPT 2009-1004 Zyprexa Patient Count by Age 8-5-09.xls, TPT 2009-1004 Zyprexa Patient Count by Age YTD 2009 8-5-09.xls
`
`
`
`
`
`
`
`
`
`8
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 3a. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009
`Share (%)
`Uses (000)
`
`TOTAL MARKET
` quetiapine fumarate
`
`
`
`Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry
`
`
`
`
`
`
`9
`
`
`(b) (4)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(b) (4)
`
`

`

`Table 3b. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009
`Share (%)
`Uses (000)
`
` aripiprazole
`
`Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09 File: PDDA 2009-1004 Dx4 by Age 8-4-09 qry
`
`
`
`
`
`
`10
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 3c. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009
`Share (%)
`Uses (000)
`
` risperidone
`
`Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09 File: PDDA 2009-1004 Dx4 by Age 8-4-09 qry
`
`
`
`
`
`
`11
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 3d. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009
`Share (%)
`Uses (000)
`
` olanzapine
`
`Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09. File: PDDA 2009-1004 Dx4 by Age 8-4-09.qry
`
`
`
`
`
`
`12
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 3e. Most Common Indications by Age Associated with the Use of Atypical Antipsychotics in Office-Based Practice Settings, 2004-2008 and YTD 2009
`Share (%)
`Uses (000)
`
` ziprasidone hcl
`
`Source: SDI: Physician Drug and Diagnosis Audit, Extracted 8-4-09 File: PDDA 2009-1004 Dx4 by Age 8-4-09 qry
`
`
`
`
`
`
`
`13
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4a. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TOTAL MARKET
`Abilify (aripiprazole)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` PED
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`
`
`Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom_Spec by Age_HMehta081309.xls
`
`
`
`
`
`
`
`
`
`
`
`
`
`14
`
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4b. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Geodon (ziprasidone)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` PA
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom_Spec by Age_HMehta081309.xls
`
`
`
`
`
`
`15
`
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4c. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Invega (paliperidone)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` PA
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom_Spec by Age_HMehta081309.xls
`
`
`
`
`
`
`16
`
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4d. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Risperdal (risperidone)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` PED
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom_Spec by Age_HMehta081309.xls and VONA Custom_Spec by Age_HMehta081709_v2.xls
`
`
`
`
`
`
`17
`
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4e. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Seroquel (quetiapine)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NEURO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`Source: SDI: Vector One®: National. Custom Run. File: Copy of VONA Custom_Spec by Age_HMehta081309.xls
`
`
`
`
`
`
`18
`
`
`(b) (4)
`
`

`

`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Table 4f. Estimated Number of Prescriptions Dispensed for Atypical Antipsychotics by Patient Age and Top 5 Physician Specialty, Years 2004 -2008 and YTD/Jun/2009
`2004
`2005
`2006
`2007
`2008
`YTD/JUN/2009
`TRxs
`Share
`N
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`TRxs
`N
`
`Share
`%
`
`Zyprexa (olanzapine)
` PSYCH
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` GP/FM/DO
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` IM
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` NP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` UNSPEC
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
` HOSP
` Age 0-2
` Age 3-6
` Age 7-12
` Age 13-17
` Age 18+
`All Others
`
`Source: SDI: Vector One®: National. Custom Run: File: Copy of VONA Custom_Spec by Age_HMehta081309.xls
`
`
`
`
`
`19
`
`
`(b) (4)
`
`

`

`Table 5a. Total Number of Mentions for Atypical Antipsychotics used Concomitantly
`with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient
`Retail Pharmacies, Jan 2004 - June 2009
`
`TOTAL MARKET
` quetiapine fumarate
`
`Occur
`(000)
`
`Share
`%
`
`Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry
`
`
`
`
`
`20
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 5b. Total Number of Mentions for Atypical Antipsychotics used Concomitantly
`with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient
`Retail Pharmacies, Jan 2004 - June 2009
`
` risperidone
`
`Occur
`(000)
`
`Share
`%
`
`Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry
`
`
`
`
`
`21
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 5c. Total Number of Mentions for Atypical Antipsychotics used Concomitantly
`with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient
`Retail Pharmacies, Jan 2004 - June 2009
`
` aripiprazole
`
`Occur
`(000)
`
`Share
`%
`
`Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry
`
`
`
`
`
`22
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 5d. Total Number of Mentions for Atypical Antipsychotics used Concomitantly
`with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient
`Retail Pharmacies, Jan 2004 - June 2009
`
` olanzapine
`
`Occur
`(000)
`
`Share
`%
`
`Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry
`
`
`
`
`
`23
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Table 5e. Total Number of Mentions for Atypical Antipsychotics used Concomitantly
`with Another Class of Products to Treat the Same Diagnosis Through U.S. Outpatient
`Retail Pharmacies, Jan 2004 - June 2009
`
` ziprasidone hcl
`
`Occur
`(000)
`
`Share
`%
`
`Source: SDI: Physician Drug and Diagnosis Audit. File: PDDA 2009-1004 Concomitant Class 8-28-09.qry
`
`
`
`
`
`24
`
`
`(b) (4)
`
`(b) (4)
`
`

`

`Appendix 2: Database Descriptions
`
`SDI Vector One®: National (VONA)
`
`SDI’s VONA measures retail dispensing of prescriptions or the frequency with which drugs move out of
`retail pharmacies into the hands of consumers via formal prescriptions. Information on the physician
`specialty, the patient’s age and gender, and estimates for the numbers of patients that are continuing or new
`to therapy are available.
`
`The Vector One® database integrates prescription activity from a variety of sources including national retail
`chains, mass merchandisers, mail order pharmacies, pharmacy benefits managers and their data systems, and
`provider groups. Vector One® receives over 2.0 billion prescription claims per year, representing over 160
`million unique patients. Since 2002 Vector One® has captured information on over 8 billion prescriptions
`representing 200 million unique patients.
`
`Prescriptions are captured from a sample of approximately 59,000 pharmacies throughout the US. The
`pharmacies in the data base account for nearly all retail pharmacies and represent nearly half of retail
`prescriptions dispensed nationwide. SDI receives all prescriptions from approximately one-third of the
`stores and a significant sample of prescriptions from the remaining stores.
`
`SDI Vector One®: Total Patient Tracker (TPT)
`SDI’s Total Patient Tracker is a national-level projected audit designed to estimate the total number of
`unique patients across all drugs and therapeutic classes in the retail outpatient setting.
`TPT derives its data from the Vector One® database which integrates prescription activity from a variety of
`sources including national ret

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket